Tango Therapeutics (United States)

company in Cambridge, United States

TNGX Nasdaq SEC CIK 1819133
Follow Tango Therapeutics (United States) Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $0 −100% vs same quarter last year
Net income −$68.4M −530.6% vs same quarter last year
EPS, diluted −$0.39 −400% vs same quarter last year
Operating cash flow −$37.1M −20% vs same quarter last year
Revenue by quarter
$4.1M
$5.4M
$3.2M
$53.8M
$0
$0
$0
$0
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
  • Revenue
  • Net income
−$150M−$100M−$50M$0$50M$100MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$62.4M−$101.6M
FY24$42.1M−$130.3M
FY23$36.5M−$101.7M
FY22$24.9M−$108.2M
FY21$37M−$58.2M
FY20$7.7M−$52M
FY19--
MarginsShare of revenue
  • Operating margin
  • Net margin
−800%−600%−400%−200%0%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY25−178.4%−162.9%
FY24−346.1%−309.7%
FY23−312.6%−278.4%
FY22−446.8%−435.1%
FY21−157.1%−157.2%
FY20−681.8%−678.8%
FY19--
Free cash flowOperating cash flow minus capital expenditure
−$200M−$100M$0$100MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$139.9M
FY24−$132.3M
FY23−$119.5M
FY22−$116.8M
FY21−$61.4M
FY20$69M
FY19-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Tango Therapeutics (United States)
  • Healthcare median
−800%−600%−400%−200%0%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearTango Therapeutics (United States)Healthcare median
FY25−162.9%−30.6%
FY24−309.7%−47%
FY23−278.4%−58%
FY22−435.1%−80.4%
FY21−157.2%−71.9%
FY20−678.8%−62.2%
FY19-−46.3%